Acambis remains neutral, Merrill Lynch says

Acambis plc was retained by Merrill Lynch analyst Peter Welford at a neutral rating after third-quarter results missed estimates on the top and bottom lines and the company recorded a gross loss. But, Merrill Lynch said it did initiate a phase 3 clinical trial for Chimerivax-JE vaccine, the most valuable program after smallpox. Shares of the Cambridge, Mass.-based biotechnology company were down 20 cents, or 2.47%, at $7.89 on volume of 14,705 shares versus the three-month running average of 21,541.5 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.